Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab Trial
This article was originally published by JDRF, and is reprinted here as part of the JDRF – Beyond Type 1 Alliance.
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was shown to able to significantly delay—for over two years—the onset of Type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of T1D.
But it doesn’t stop there. JDRF has updated results, and this is big.
The investigators were able to follow up on the individuals who didn’t develop clinical diabetes, and the effect of teplizumab had been sustained: 50% of those treated with teplizumab remain diabetes-free, compared to only 22% of those taking placebo, and the delay in diabetes onset was close to 3 years (35 months).
These were presented by Emily Sims, M.D., an assistant professor of pediatrics at Indiana University and a JDRF-funded investigator, at ADA’s Scientific Sessions.
Additionally, the participants, both the teplizumab and placebo groups, had a progressive decline in the biomarker that measure’s the body’s ability to produce insulin—C-peptide—preceding the trial. But the teplizumab team found that production of C-peptide actually went up following treatment with teplizumab, especially in the first 6 months after treatment. Like, teplizumab could reverse the downward trajectory of C-peptide loss that was there before the trial.*
And there’s more: the increases in C-peptide were correlated with induction of a state of “exhaustion” in “bad” immune cells. Like, they literally took a punch and lost the ammo to keep on attacking the beta cells.
So, could the exhaustion of “bad” immune cells result in not getting T1D or significantly slowing down the time to getting it? Well, we’re not there yet, but we’re close, and closer to a day when T1D might be prevented, forever.
Watch Dr. Sims discuss the findings below
*In the placebo group, C-peptide still declined.
Click here for complete coverage of ADA 2020 from Beyond Type 1.